# Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis

> **NCT03469336** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 18 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** PF-06763809
- **OTHER:** Vehicle
- **DRUG:** Calcipotriene/calcipotriol
- **DRUG:** Betamethasone

## Key facts

- **NCT ID:** NCT03469336
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-24
- **Primary completion:** 2019-03-20
- **Final completion:** 2019-03-20
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03469336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03469336, "Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03469336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*